On the other hand, eIF2α hyperphosphorylation correlated with better disease-free survival and favorable clinical outcomes for patients with stomach, colon and sigma-rectum carcinomas [68], non-small cell lung cancer (NSCLC) [69], and triple-negative breast cancer (TNBC) [70]. This evidence concerns the gene EIF2A and triple-negative breast carcinoma.